Inhibiting Tyrosine Kinases: Successes and Limitations

نویسندگان

چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Inhibiting phosphoinositide 3-kinases.

ISSN: 1538-4047 (Print) 1555-8576 (Online) Journal homepage: http://www.tandfonline.com/loi/kcbt20 Inhibiting phosphoinositide 3-kinases Yardena Samuels, Jiuxiang Zhu & Christoph Lengauer To cite this article: Yardena Samuels, Jiuxiang Zhu & Christoph Lengauer (2005) Inhibiting phosphoinositide 3-kinases, Cancer Biology & Therapy, 4:5, 546-547, DOI: 10.4161/cbt.4.5.1669 To link to this article:...

متن کامل

Tyrosine Kinases in Cancer

Articles should focus on tyrosine kinases in cancer and may include the following topics: Tyrosine kinases. § § Includes both tyrosine kinases and receptor tyrosine kinases, roles, including extracellular and intracellular signaling cascades. Aberrant tyrosine kinases § § Abnormalities including point mutations, chromosomal translocations and downstream effects of constitutive activation. Disea...

متن کامل

Bacterial Protein-Tyrosine Kinases

Bacteria and Eukarya share essentially the same family of protein-serine/threonine kinases, also known as the Hanks-type kinases. However, when it comes to protein-tyrosine phosphorylation, bacteria seem to have gone their own way. Bacterial protein-tyrosine kinases (BY-kinases) are bacterial enzymes that are unique in exploiting the ATP/GTPbinding Walker motif to catalyze phosphorylation of pr...

متن کامل

Successes and limitations of targeted therapies in renal cell carcinoma.

Until recently, the standard treatment for metastatic renal cell carcinoma (RCC) was nonspecific immunotherapy based on interleukin-2 or interferon-α. This was associated with a modest survival benefit and with significant clinical toxicities. The understanding of numerous molecular pathways in RCC, including HIF, VEGF, mTOR, and the consecutive use of targeted therapies since the beginning of ...

متن کامل

Successes and limitations of targeted cancer therapy in lung cancer.

Human cancers usually evolve through multistep processes. These processes are driven by the accumulation of abundant genetic and epigenetic abnormalities. However, some lung cancers depend on a single activated oncogene by somatic mutation, termed 'driver oncogenic mutations', for their proliferation and survival. EGFR(epidermal growth factor receptor) mutations and ALK(anaplastic lymphoma kina...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Cancer Biology & Therapy

سال: 2003

ISSN: 1538-4047,1555-8576

DOI: 10.4161/cbt.206